antibody-drug conjugate

ASCO puts spotlight on advancing antibody-drug conjugate pipeline
ASCO puts spotlight on advancing antibody-drug conjugate pipeline
BioPharma Dive
ASCO 2023
antibody-drug conjugate
Merck
BioNTech
Daiichi Sankyo
Flag link:
Byondis' breast cancer drug fails to bloom as FDA denies approval
Byondis' breast cancer drug fails to bloom as FDA denies approval
Fierce Biotech
Byondis
antibody-drug conjugate
FDA
breast cancer
HER-2 positive breast cancer
Flag link:
Astellas, Sony Team on Novel ADC Platform for Oncology
Astellas, Sony Team on Novel ADC Platform for Oncology
BioSpace
Astellas
Sony Corporation
antibody-drug conjugate
oncology
Flag link:
AstraZeneca Expands ADC Portfolio with $600M Deal with LaNova
AstraZeneca Expands ADC Portfolio with $600M Deal with LaNova
BioSpace
AstraZeneca
antibody-drug conjugate
LaNova Medicines
Flag link:
Eisai Pays up to $2B for ADC Bearing Its Halaven as Payload
Eisai Pays up to $2B for ADC Bearing Its Halaven as Payload
BioSpace
Eisai
Bliss Biopharmaceutical
clinical trials
antibody-drug conjugate
Halaven
Flag link:
Biopharma Bets Big on Antibody-Drug Conjugates
Biopharma Bets Big on Antibody-Drug Conjugates
BioSpace
antibody-drug conjugate
Merck
Seagen
M&A
AstraZeneca
BioNTech
Bristol Myers Squibb
Flag link:
BMS signs ADC development deal with Munich-based biotech worth more than $1B
BMS signs ADC development deal with Munich-based biotech worth more than $1B
Medical Marketing and Media
Bristol Myers Squibb
Tubulius
cancer
solid tumors
antibody-drug conjugate
Flag link:
Takeda taps Innate for a new celiac approach
Takeda taps Innate for a new celiac approach
EP Vantage
Takeda
celiac disease
Innate Pharma
antibody-drug conjugate
Flag link:
BioNTech Adds Two ADCs in Second Deal in as Many Months
BioNTech Adds Two ADCs in Second Deal in as Many Months
BioSpace
BioNTech
antibody-drug conjugate
solid tumors
Duality Biologics
Flag link:
Takeda opens 4th front in assault on celiac, tapping Innate to develop antibody-drug conjugates
Takeda opens 4th front in assault on celiac, tapping Innate to develop antibody-drug conjugates
Fierce Biotech
Takeda
celiac disease
antibody-drug conjugate
Innate Pharma
Flag link:
AbbVie sidelines CytomX after seeing midphase oncology ADC data, opens talks on returning lead drug
AbbVie sidelines CytomX after seeing midphase oncology ADC data, opens talks on returning lead drug
Fierce Biotech
AbbVie
CytomX Therapeutics
cancer
oncology
antibody-drug conjugate
Flag link:
FDA pauses Mersana’s clinical trial after patient dies
FDA pauses Mersana’s clinical trial after patient dies
Endpoints
Mersana
clinical trials
FDA
patient death
cancer
XMT-2056
antibody-drug conjugate
Flag link:
Vertex pays ImmunoGen $15M to use antibody-drug conjugates to improve CRISPR therapy
Vertex pays ImmunoGen $15M to use antibody-drug conjugates to improve CRISPR therapy
Fierce Biotech
Vertex Pharmaceuticals
Immunogen
gen editing
antibody-drug conjugate
exa-cel
Flag link:
AstraZeneca strengthens its oncology R&D with in-licensing of CMG901 from China-based biotech KYM Biosciences
AstraZeneca strengthens its oncology R&D with in-licensing of CMG901 from China-based biotech KYM Biosciences
Medical Marketing and Media
AstraZeneca
CMG901
antibody-drug conjugate
gastric cancer
KYM Biosciences
Flag link:
AstraZeneca doubles down on hot cancer target, paying $63M for ADC months after bispecific deal
AstraZeneca doubles down on hot cancer target, paying $63M for ADC months after bispecific deal
Fierce Biotech
AstraZeneca
Claudin18.2
KYM Biosciences
antibody-drug conjugate
pancreatic cancer
Flag link:
In flux, CDMO Abzena lays off 66 in San Diego days after hiring new CEO and reshuffling board
In flux, CDMO Abzena lays off 66 in San Diego days after hiring new CEO and reshuffling board
Fierce Pharma
Abzena
CDMOs
layoffs
antibody-drug conjugate
Flag link:
Sutro shells out latest update on ovarian cancer treatment, plans for pivotal trial
Sutro shells out latest update on ovarian cancer treatment, plans for pivotal trial
Endpoints
Sutro BioPharma
clinical trials
antibody-drug conjugate
ovarian cancer
luveltamab tazevibulin
Flag link:
Amgen piles $2B more into pharma's ADC rush in Synaffix pact
Amgen piles $2B more into pharma's ADC rush in Synaffix pact
Fierce Biotech
Amgen
antibody-drug conjugate
Synaffix
Flag link:
ADC deals: Mersana engages with Merck, LegoChem and Amgen collaborate
ADC deals: Mersana engages with Merck, LegoChem and Amgen collaborate
Biopharma Reporter
antibody-drug conjugate
Merck
LegoChem Biosciences
Mersana
Amgen
GSK
Janssen
Flag link:
Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal
Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal
BioSpace
Merck
China
Kelun-Biotech
antibody-drug conjugate
oncology
Flag link:

Pages